Cushing's Syndrome Clinical Trial
OBJECTIVES: I. Study the relationship between dysregulation of the
hypothalamic-pituitary-adrenal (HPA) axis and disorders of mood, vegetative function, and
cognition in patients with Cushing's disease.
II. Identify subgroups of patients with Cushing's disease who differ in the presence and
severity of the depressive syndrome, and uncover HPA axis dysregulation differences among
them using corticotropin-releasing hormone, metyrapone, and dexamethasone challenge testing.
PROTOCOL OUTLINE: All patients receive a psychiatric evaluation at baseline, as well as
assessments of plasma adrenocorticotropin, beta lipotropin, beta endorphin, and cortisol,
and urinary cortisol. Peptide and steroid assays are performed, alone and in response to
corticotropin-releasing hormone, metyrapone, and dexamethasone. Patients are given sleep
electroencephalograms at baseline and 1 year following treatment.
A weight maintenance diet is prescribed for all patients.
;
Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02468193 -
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
|
Phase 2 | |
Recruiting |
NCT00457587 -
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
|
||
Completed |
NCT00006278 -
Study of Cushing's Syndrome Not Related to ACTH Production
|
N/A | |
Completed |
NCT00361777 -
Diagnostic Performance of Screening Tests for Cushing s Syndrome
|
||
Completed |
NCT03606408 -
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
|
Phase 2 | |
Completed |
NCT02663609 -
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
|
||
Recruiting |
NCT01504555 -
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
|
Phase 3 | |
Active, not recruiting |
NCT00004343 -
Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome
|
N/A | |
Completed |
NCT02922257 -
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
|
||
Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
Terminated |
NCT00422201 -
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
|
Phase 2 | |
Completed |
NCT00001180 -
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
|
N/A | |
Completed |
NCT02804750 -
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
|
Phase 2 | |
Completed |
NCT00936741 -
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
|
Phase 3 | |
Completed |
NCT03817840 -
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
|
||
Completed |
NCT01959711 -
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy
|
Phase 4 | |
Completed |
NCT05633953 -
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
|
||
Completed |
NCT02889224 -
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
|
N/A | |
Terminated |
NCT00796783 -
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
|
N/A | |
Recruiting |
NCT02019706 -
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
|
Phase 2 |